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Abstract
Objective: Evaluating clinical and hematological-clinical parameters 
of patients with sickle cell anemia (SCA) before and after four years 
of using hydroxyurea (HU). 
Method: A retrospective cohort study implementing a quantitative, 
descriptive and analytical approach developed in two public teaching 
hospitals located in the Central-West region of Brazil, from November 
2010 to October 2011. Data collection was performed through medical 
records of 32 patients with SCA to assess clinical and hematological 
parameters before and after HU treatment. The study was approved 
by the UFMS Ethics Committee under protocol number 1890/2010. 
Results: All of the 32 patients were homozygous with a mean age 
in the prescription of hydroxyurea of 19.72±7.58 years, an initial dose 
of 15.59±4.27 mg/kg/day, and 22.48±5.35 mg/kg/day in the fourth 
year of treatment. Regarding the use of HU, average values of some 
hematological parameters presented a significant difference in the 
fourth year compared to the mean values prior to HU use, such as 
fetal hemoglobin (14.49±7.52%), red blood cells (2.54±0.38x1012/L), 
hematocrit (25.30±4.03%) and hemoglobin (9.22±3.34g/dL). 
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Introduction
Sickle-cell anemia (SCA) is a result of an autoso-
mal recessive genetic disorder, with the exchange 
of two amino acids at position 6 of the β globin 
chain when glutamic acid (GAG) is exchanged for 
valine (GTG), resulting in a structural change in the 
peptide chain [1], characterized by the presence of 
homozygous hemoglobin S (HbSS) in double het-
erozygosity (HbAS) with other abnormal hemoglo-
bins (HbSC, HbSD, among others) or in interaction 
with thalassemias (alpha or beta) [2]. 
Hemoglobin S (HbS) in deoxygenation suffer 
physicochemical changes, polymerizing and assum-
ing a sickle shape. Decreased deformability makes 
blood flow slow, and depending on HbS concentra-
tion and deoxygenation, the aggregation of these 
molecules can lead to vasocclusion. This phenom-
enon is responsible for acute and chronic manifesta-
tions that can affect organs and systems from the 
first year of being affected and last throughout the 
life of affected individuals [3].
Episodes resulting from vasocclusion such as 
painful crises, Acute Thoracic Syndrome (ATS), and 
stroke/cerebrovascular accident (CVA), among oth-
ers, cause suffering to the patient and to caregiv-
ers/family members [4]. Seeking to mitigate this 
condition, the therapeutic approach for SCA favors 
attempts to replace HbS production by fetal hemo-
globin (HbF), with the aim to alter spinal prolifera-
tion in order to facilitate F cell production kinetics. 
Fetal hemoglobin (HbF) is predominant in fetal cells 
and produced from proeritroblasts clones as a result 
of immature erythrocyte precursors, which uniquely 
activate genes and increase HbF levels [5-7].
The effect of hydroxyurea on the painful episodes 
of SCA was verified by the Multicenter Study of 
Hydroxyurea (MSH) in Sickle Cell Anemia, through a 
randomized double-blinded clinical trial conducted 
with 299 participants. The MSH related that therapy 
reduces painful crises and the number of transfu-
sions required [8]. Moreover, hydroxyurea (HU) 
therapy demonstrated effectiveness in improving 
hematological parameters in patients [9]. 
A MSH long-term follow-up study of 17.5 years 
verified survival of SCA patients treated with HU 
and found that long-term use of the drug was safe 
and could reduce mortality [10]. Another retrospec-
tive study in adult patients evaluated the effect of 
HU dosage on the HbF response, organ damage 
and survival of patients using the drug, and it found 
that patients should be treated with the maximum 
tolerated dose before organ damage occurs [11]. 
Recommendations for health professionals were 
shown by a panel of experts, including in relation 
to HU treatment [12].
Considering the published evidence and reports 
of SCA patients undergoing HU treatment, we rea-
lized the need to investigate whether there is a po-
sitive relationship between exposure to hydroxyurea 
and increased fetal hemoglobin, as well as whether 
there is a positive relationship between the use of 
hydroxyurea and improvement of hematological pa-
rameters. Thus, the following was adopted as the 
guiding question for this study: What are the effects 
Conclusion: Treatment with hydroxyurea showed a significant in-
crease in fetal hemoglobin levels, increased hemoglobin, hematocrit 
and average corpuscular hemoglobin concentration, with reduced epi-
sodes of pain, infection and acute chest syndrome in such a way as 
to reaffirm its efficiency in treating these patients.
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of using hydroxyurea in relation to the clinical and 
hematological parameters of patients with sickle cell 
anemia?
In this perspective, this study aimed to evaluate 
the clinical and hematological parameters of pa-
tients with sickle cell anemia before and after four 
years of using hydroxyurea.
Method
This is a descriptive and analytical retrospective co-
hort study with a quantitative approach, develo-
ped in two public teaching hospitals located in the 
center-west region of Brazil from November 2010 
to October 2011. Data collection was conducted 
from the medical records of 32 patients with SCA 
in order to evaluate the clinical and hematological 
parameters before and after HU treatment. 
A time interval of thirteen years for including 
participants to be evaluated was established, co-
rresponding to the years between 1998 and 2010. 
This period was established since it corresponded 
to the period in which the studied services regis-
tered patients treated with HU and provided the 
necessary information for evaluating the use of this 
medicine.
Patients with confirmed electrophoretic profile 
for HbSS with medical indication for HU therapy, 
a medical diagnosis confirmed by ICD10 D57.0 and 
D57.1, which correspond to cases of sickle cell ane-
mia with and without crisis, respectively, in addition 
to undergoing HU treatment for a minimum period 
of four years were included in the study. Medical 
records of patients diagnosed with other hemoglo-
binopathies and patients undergoing HU for a pe-
riod of less than four years were excluded.
A data collection instrument was developed spe-
cifically for systematizing the information extrac-
tion necessary for this study. The variables adopted 
(Table 1) were adapted from the Ministry of Health 
of Brazil MS/SAS number 55/2010 [13], which es-
tablishes the Clinical Protocol and the therapeutic 
guidelines for sickle cell disease in the country.
In order to evaluate the effect of HU treatment 
in patients with sickle cell disease, the studied va-
riables were organized into two moments, being 
before and after therapy. The "before" refers to 
data recorded in the period one year prior to using 
the drug, and the "after" corresponds to the four-
th year of use. The four-year period was stipulated 
in this study as a safety margin, considering that 
the MS/SAS Ordinance number 55/2010 requires a 
Table 1.  Data collected from charts of patients' with sickle cell anemia to perform the study. Campo 
Grande/MS, Brazil, 2016.
Sociodemographic Variable Clinical Variables Hematological Variables
• Date of birth. • Acute thoracic syndrome (ATS). 
• Cerebral Vascular Accident 
(CVA).
• Infections.
• Cholelithiasis.
• Pneumonia.
• Pain Crisis.
• Priapism.
• Number of Transfusions. 
• Hydroxyureia (date and 
initial dose and at 4 years of 
treatment)*.
• Fetal Hemoglobin - Hb F (%). 
• Red Blood Cells - RBC (1012/L). 
• Hematocrit - Hct (%). 
• Total Hemoglobin concentration - Hb (g/dL). 
• Mean corpuscular hemoglobin concentration - 
MCHC (g/dL). 
• Mean Corpuscular Hemoglobin - MCH (pg). 
• Mean corpuscular volume - MCV (fL). 
• Leukocytes - WBC (109/L). 
• Platelets - PLT (µL) and neutrophils ANC (%).
*:  Each patient’s weight and the prescribed HU dose in the medical record were used to obtain the individual mg/kg ratio 
of the HU dosage. The simple three rule was used for the calculation, obtaining the initial dose/kg/day per patient and 
the final dose in the fourth year of using HU. The initial and after four years of using dosage means were calculated from 
the individual dosage.
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minimum interval of two years for evaluating HU 
treatment [13].
Data were collected in the first semester of 
2012. The events were recorded in an Excel® 2010 
spreadsheet according to the diagnosis established 
in the medical records. EpiInfo version 3.4.1 and 
Bio-Stat 4.0 [14] were used for data analysis, with 
descriptive analysis and tabular representation of 
the results.
Student's t-test for paired samples and Wilcoxon 
test were used to compare the means of the quan-
titative variables in the two moments evaluated. 
Both tests were used after checking the distribu-
tion normality by the Kolmogorov-Smirnov Test. A 
significance level of 5% was adopted.
This study was approved by the Research Ethics 
Committee of the Federal University of Mato Grosso 
do Sul under Protocol number 1890/2010, in ac-
cordance with the current national legislation for 
human research.
Results
The mean age of the 32 patients at the start of 
their HU treatment was 19.72±7.58 years. The mean 
initial dose of HU was 15.59±4.27 mg/kg/day, and 
22.48±5.35 mg/kg/day in the fourth year.
In comparing mean values of hematological param-
eters before and after HU use, HbF (14.49±7.52%), 
RBC (2.54±0.38x1012/L), Hct (25.30±4.03%) and 
Hb (9.22±3.34 g/dL) presented significant differ-
ences (p<0.001). The mean parameter values in 
the fourth year for HCM (35.07±4.99pg, p<0.003), 
PLT (327,029±110,503 μl, p<0.002) and ANC 
(6,586.53±2,643.90, p<0.03) were also significant. 
No statistically significant results were found in com-
paring MCHC and MCV (Table 2). 
In comparing the number of episodes resulting 
from vasoconstriction before and after the use of 
HU, the following results were observed: Crisis (102 
to 72), Infection (48 to 15), Pneumonia (33 to 16) 
and ATS (Acute Thoracic Syndrome) (12 to 2). The 
comparison between the number of blood transfu-
sions at both moments presented an occurrence of 
10.0±8.0 for 7.0±6.0 procedures (Table 3). 
Table 2.  Hematologic parameters of patients with 
sickle cell anemia before and after four 
years of using hydroxyurea, Campo Gran-
de/MS, Brazil, 2016 (n = 32).
Hematologic 
parameters
Hydroxyureia
pBefore using
After 4 years of 
using
Mean SD Mean SD
HbF (%) 7.59 5.22 14.49 7.52 <0.0011
He (1012/L) 2.26 0.30 2.54 0.38 <0.0011
Hct (%) 21.88 3.55 25.30 4.03 <0.0011
Hb (g/dL) 8.17 3.15 9.22 3.34 <0.0012
MCHC 
(g/dL)
32.88 1.88 33.21 2.48 0.7302
MCH (pg) 32.46 3.40 35.07 4.99 0.0031
MCV (fL) 101.79 11.96 99.51 19.45 0.9102
Leukocytes 
WBC (109/L)
12.657 3.986 11.126 3.766 0.0801
PLT (µL) 290.333 106.696 327.029 110.503 0.0022
1: Student’s T-test for paired samples. 2: Wilcoxon Test.
Table 3.  Complications due to vasoconstriction in 
patients with sickle cell anemia before and 
after four years of using hydroxyurea. Cam-
po Grande/MS, Brazil, 2016 (n = 32).
Hematologic 
parameters
Hydroxyureia
reduction 
(%)Before 
using
After 4 years of 
using
CVA 4 1 75.0
ATS 12 2 83.3
Infections 48 15 68.7
Cholelithiasis 17 8 52.9
Pneumonia 33 16 51.5
Pain crises 102 72 29.4
Priapism 1 - *
N° of transfusions 10 7 30.0
*: low frequency.
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Discussion
The patients’ mean age at the time of HU treatment 
initiation was 19.72±7.58 years with varying doses, 
where the mean in the first year was 15.59±4.27 
mg/kg/day and 22.48±5.35 mg/kg/day in the four-
th year. These data were similar to those found in 
a prospective cohort study on the effects of HU 
conducted with SCA patients over 18 years of age 
administered a mean dose of 21 mg/kg/day, ranging 
from 10 to 35 mg/kg [15].
The gradual scaling regimen recommended by 
Ordinance MS/SAS number 55/2010 of the Minis-
try of Health of Brazil is initially a single dose of 15 
mg/kg/day, with a gradual increase not exceeding 
the maximum tolerated dose of 35 mg/kg/day.12 
The maximum tolerated dose approved by the Food 
and Drug Administration (FDA) for moderate and 
severe adult patients is up to 35mg/kg/day [16]. A 
daily oral dose of 25 to 30 mg/kg was tested and 
well tolerated by the majority of children aged 5 to 
15 years participating in a study conducted in the 
United States [17].
The presented HbF values were significantly hig-
her in the fourth year of HU treatment (14.49%) 
compared to the mean of the year before adminis-
tration of the drug (7.59%). An observational study 
was conducted investigating 32 patients regarding 
HU scaling dosage, of which 26 were treated with 
the maximum tolerated dose (ranging from 10 to 35 
mg/kg) for two to 38 weeks, and showed an increa-
se in HbF (4.0±2% to 15±6%) among the analyzed 
laboratory parameters [15].
In response to the drug’s effects, another study 
revealed that two patients treated with HU had an 
increase in young fetal cells between 48 and 72 
hours, which resulted in a high level of HbF [18]. A 
multicenter American study evaluated the safety of 
HU therapy in children aged 5 to 15 years, and as 
a result 69 children achieved the highest tolerated 
dose of HU (25.6±6.2 mg/kg/day), resulting in a 
higher production of HbF (17.8±7.2%) compared to 
the initial treatment parameter (7.3±4.9%) [17].
In this study, a significant increase in red blood 
cell count (2.54 1012/L, p<0.001) and hematocrit 
(25.30%, p<0.001) was found in the fourth year 
of HU use in comparison to the year before insti-
tuting the drug. These results are similar to those 
described in an English study, which showed that 
erythrocyte alterations due to the effect of HU cau-
se an elevation of Hb and Hct, in addition to hydra-
ting and improving erythrocyte survival.9 In another 
study, an increase in MCV and HbF was observed, 
however with reductions in leukocyte, platelet, re-
ticulocyte, neutrophil and total bilirubin counts [17]. 
MCHC ranged from 32.88g/dL in the year prior to 
instituting therapy to 33.21g/dL in the fourth year of 
HU treatment. The same occurred with MCV, which 
initially presented a result of 99.51fL and 101.79fL 
in the fourth year; however, none of these had a 
significant relation when compared to the average 
of the year prior to instituting the drug, but remai-
ned within the reference values of the present stu-
dy. These data do not corroborate with published 
evidence, suggesting that MCV is directly related to 
the increase in HbF [9].
When the MCV and HbF were analyzed to-
gether with the HU dosage, the results of this stu-
dy showed that MCV levels in the fourth year did 
not have the expected increase. Scientific evidence 
regarding HU therapy emphasizes that there may 
be failures during treatment, including the fact of 
non-monitoring not only regarding medication use, 
but also regarding requesting of laboratory results 
in a systematic way, age at the time of indication 
and/or institution of the drug, ideal dosage, among 
others [19]. The studies in which the maximum to-
lerated dose was reached probably registered the 
best results [9].
In the fourth year, leukocytes were reduced to 
11.12x109/L (±3.76x109/L; p=0.080), but remained 
within the reference values. In a retrospective study 
conducted in the US with 383 adult patients with 
sickle cell anemia between 2001 and 2010, absolute 
neutrophil count (ANC) was lower in the last consul-
InternatIonal archIves of MedIcIne 
sectIon: heMatology
ISSN: 1755-7682
2017
Vol. 10 No. 199
doi: 10.3823/2469
This article is available at: www.intarchmed.com and www.medbrary.com 6
tation for the group receiving HU (4.9%; p<0.001) 
[11]. However, it has been concluded that adults 
should be treated with the maximum tolerated dose 
of HU, preferably before organ damage.
In the fourth year, neutrophils (7,729.25%, 
p=0.030) and hemoglobin (9.22 g/dL, p<0.001) va-
lues showed a significant relationship when compa-
red to the mean of the year prior to instituting the 
drug. In an observational study also conducted in 
the United States, neutropenia (73%), reticulocyto-
penia (22%) and a decrease in Hb concentration 
(1%) were detected at the moment of HU dose ad-
justment [15].
To monitor dose adjustment, neutrophil count, 
platelet count, reticulocyte count, and hemoglobin 
level may not be less than 2,000/mm3, 80,000/
mm3, 80,000/mm3, and 4.5 g/dL, respectively [5, 
13]. Bone marrow suppression may occur, but it 
is reversible and transient with discontinuation of 
treatment, and specifically for granulocyte series, 
it represents a common adverse effect in patients 
treated with HU. The most frequent adverse events 
include neutropenia and thrombocytopenia, as well 
as anemia to a lesser extent [5, 20].
Platelets remained within the reference values 
when compared to the mean of the year prior to in-
stituting the drug (327,029 to 290,333 μL, p=0.002). 
An observational follow-up study originating from 
MSH evaluated the effects of HU on mortality and 
morbidity in 233 adults with sickle cell disease be-
tween 1996 and 2001. In this study, a subgroup 
of 63 patients with smaller reticulocyte counts 
(<250.000/mm3) and Hb levels of <9g/dL, also pre-
sented platelets within in the reference parameter 
after two years of HU treatment (401,700±146,900 
μL) [21].
Pain episodes due to vasoconstriction were re-
duced after HU treatment (102 to 72). It should be 
mentioned that the key point of the MSH study 
was a significant reduction of pain episodes [8]. Im-
provement in erythrocyte deformity makes erythro-
cytes more spherical, and morphological changes in 
conjunction with rheology can represent a potential 
benefit to patients with sickle cell disease [16]. HU 
acts from proeritroblast precursors, favoring red cell 
production with a high level of Hb F [4], and in this 
way partially inhibits polymerization and avoids fal-
cization in deoxy-HbS conditions with a consequent 
reduction in painful crises [22].
After four years of HU treatment, lung infections 
(specifically pneumonia) reduced from 33 to 16 
episodes. Splenic function (which is decreased in 
SCA) is one of the factors that contribute to greater 
susceptibility to infections. Over time, infections in 
SCA patients can affect organs from already dama-
ged systems, such as lungs damaged by recurrent 
pneumonia, kidneys afflicted by urinary infections 
and bones with osteomyelitis. Bacterial, viral and 
parasitic infections cause greater morbidity and are 
difficult to control [3].
ATS and CVA episodes resulting from vasocclu-
sion reduced from 12 to two cases and from four 
to one, respectively, after HU use. The MSH study 
demonstrated the efficacy of this drug in reducing 
pain episodes following UH therapy over placebo 
[8].
The mean number of blood transfusions in the 
fourth year of HU use was reduced from 10 to 
7 transfusions in comparison to the year before 
treatment. In the MSH study, 299 severely affec-
ted adults with three or more pain episodes/year 
in the HU group had reduced transfusions (73 to 
48, p=0,001) [8].
Scientific evidence has demonstrated the efficacy 
of HU in reducing the frequency of painful episo-
des,8 improving hematological parameters [13] and 
toxicity without serious side effects.17 Therefore, the 
results of this study have demonstrated that HU the-
rapy remains an option to be offered in order to 
benefit a larger number of patients with sickle cell 
disease worldwide.
Reticulocytes were not collected in this study be-
cause of the lack of systematic registering in medical 
records. Thus, hemolysis markers were not analy-
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zed, representing a limiting factor of this study, in 
addition to having data collection from secondary 
and retrospective sources.
Conclusion
The effects of hydroxyurea on hematological pa-
rameters demonstrate a significant increase in the 
level of HbF, improving Hb, RBC, Hct, and MCH 
concentration and reducing absolute neutrophils. 
The use of this therapy decreases painful crises, in-
fection (pneumonia) and ATS.
This study considerably contributes to SCA knowl-
edge, as it provides evidence of improved treatment 
conditions which may lead to effective interventions 
for patients with sickle cell disease in health services.
It is up to health systems to ensure the use of this 
drug as a treatment option for patients with sickle 
cell disease. We suggest future investigations that 
evaluate the efficacy of HU and the ideal dosage 
through experimental and epidemiological studies 
involving large populations. 
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